In this randomized trial of post-transcatheter aortic valve replacement patients with atrial fibrillation, edoxaban was noninferior to vitamin K antagonists with regard to a composite of adverse endpoints, but was associated with a higher rate of major bleeding.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.